{"transactions":[{"id":710120,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Restricted stock Units","published_at":"2026-07-14T20:00:19.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 2,000 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":2000,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001493152-26-033166","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033166/ownership.xml","form_type":"4"}},{"id":719579,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-07-02T19:00:27.000Z","date":"2026-07-01","kind":"purchase","planned":false,"acquired":true,"shares":240000,"price":0.0431,"value":10344.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431."}],"balance_after":94124319,"source":{"system":"sec-edgar","filing":"0001493152-26-031846","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226031846/ownership.xml","form_type":"4"}},{"id":728177,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-25T00:37:38.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":65000,"price":0.045,"value":2925.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."}],"balance_after":93694319,"source":{"system":"sec-edgar","filing":"0001493152-26-029997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029997/ownership.xml","form_type":"4"}},{"id":728176,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-25T00:37:38.000Z","date":"2026-06-23","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":0.045,"value":3375.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."}],"balance_after":93769319,"source":{"system":"sec-edgar","filing":"0001493152-26-029997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029997/ownership.xml","form_type":"4"}},{"id":728175,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-25T00:37:38.000Z","date":"2026-06-24","kind":"purchase","planned":false,"acquired":true,"shares":115000,"price":0.045,"value":5175.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045."}],"balance_after":93884319,"source":{"system":"sec-edgar","filing":"0001493152-26-029997","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029997/ownership.xml","form_type":"4"}},{"id":735083,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-17T23:34:05.000Z","date":"2026-06-15","kind":"purchase","planned":false,"acquired":true,"shares":96000,"price":0.045,"value":4320.0,"ownership":{"direct":true},"balance_after":93389560,"source":{"system":"sec-edgar","filing":"0001493152-26-029137","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029137/ownership.xml","form_type":"4"}},{"id":735082,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2026-06-17T23:34:05.000Z","date":"2026-06-17","kind":"purchase","planned":false,"acquired":true,"shares":239759,"price":0.0446,"value":10693.2514,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446."}],"balance_after":93629319,"source":{"system":"sec-edgar","filing":"0001493152-26-029137","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029137/ownership.xml","form_type":"4"}},{"id":931520,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-01-26T22:15:27.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":4426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated January 21, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."}],"balance_after":8491,"derivative":{"underlying":"Common Stock","underlying_shares":4426000},"source":{"system":"sec-edgar","filing":"0001493152-26-003634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226003634/ownership.xml","form_type":"4"}},{"id":994570,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-11-19T20:45:27.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":4065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated November 17, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis."}],"balance_after":4065,"derivative":{"underlying":"Com-mon Stock","underlying_shares":4065000},"source":{"system":"sec-edgar","filing":"0001493152-25-024236","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225024236/ownership.xml","form_type":"4"}},{"id":1089717,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-07-10T21:15:14.000Z","date":"2025-07-08","kind":"purchase","planned":false,"acquired":true,"shares":94736,"price":0.005,"value":473.68,"ownership":{"direct":true},"balance_after":93388297,"source":{"system":"sec-edgar","filing":"0001641172-25-018620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000164117225018620/ownership.xml","form_type":"4"}},{"id":1089716,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-07-10T21:15:14.000Z","date":"2025-07-09","kind":"purchase","planned":false,"acquired":true,"shares":1,"price":0.005,"value":0.005,"ownership":{"direct":true},"balance_after":93293561,"source":{"system":"sec-edgar","filing":"0001641172-25-018620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000164117225018620/ownership.xml","form_type":"4"}},{"id":1089715,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-07-10T21:15:14.000Z","date":"2025-07-10","kind":"purchase","planned":false,"acquired":true,"shares":104000,"price":0.005,"value":520.0,"ownership":{"direct":true},"balance_after":93293560,"source":{"system":"sec-edgar","filing":"0001641172-25-018620","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000164117225018620/ownership.xml","form_type":"4"}},{"id":1290020,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-01-31T22:08:22.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":63775,"price":0.028,"value":1785.7,"ownership":{"direct":true},"balance_after":93189560,"source":{"system":"sec-edgar","filing":"0001493152-25-004486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225004486/ownership.xml","form_type":"4"}},{"id":1290019,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-01-31T22:08:22.000Z","date":"2025-01-30","kind":"purchase","planned":false,"acquired":true,"shares":100003,"price":0.028,"value":2800.084,"ownership":{"direct":true},"balance_after":93125785,"source":{"system":"sec-edgar","filing":"0001493152-25-004486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225004486/ownership.xml","form_type":"4"}},{"id":1290018,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2025-01-31T22:08:22.000Z","date":"2025-01-29","kind":"purchase","planned":false,"acquired":true,"shares":183066,"price":0.028,"value":5125.848,"ownership":{"direct":true},"balance_after":93025782,"source":{"system":"sec-edgar","filing":"0001493152-25-004486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315225004486/ownership.xml","form_type":"4"}},{"id":1351625,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-11-26T16:33:58.000Z","date":"2024-11-22","kind":"purchase","planned":false,"acquired":true,"shares":298499,"price":0.0289,"value":8626.6211,"ownership":{"direct":true},"balance_after":92842716,"source":{"system":"sec-edgar","filing":"0001493152-24-047762","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315224047762/ownership.xml","form_type":"4"}},{"id":1422441,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2024-08-27T12:00:06.000Z","date":"2024-08-23","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":0.02,"value":10000.0,"ownership":{"direct":true},"balance_after":92544217,"source":{"system":"sec-edgar","filing":"0001493152-24-033939","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315224033939/ownership.xml","form_type":"4"}},{"id":1841451,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-30T13:25:05.000Z","date":"2023-06-28","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":0.026,"value":1950.0,"ownership":{"direct":true},"balance_after":91619217,"source":{"system":"sec-edgar","filing":"0001493152-23-023015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223023015/ownership.xml","form_type":"4"}},{"id":1841450,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-30T13:25:05.000Z","date":"2023-06-29","kind":"purchase","planned":false,"acquired":true,"shares":425000,"price":0.021,"value":8925.0,"ownership":{"direct":true},"balance_after":92044217,"source":{"system":"sec-edgar","filing":"0001493152-23-023015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223023015/ownership.xml","form_type":"4"}},{"id":1850528,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-20T16:00:06.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.026,"value":2600.0,"ownership":{"direct":true},"balance_after":91544217,"source":{"system":"sec-edgar","filing":"0001493152-23-021800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223021800/ownership.xml","form_type":"4"}},{"id":1853229,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-06-16T16:00:08.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":0.0326,"value":13040.0,"ownership":{"direct":true},"balance_after":91444217,"source":{"system":"sec-edgar","filing":"0001493152-23-021563","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223021563/ownership.xml","form_type":"4"}},{"id":1873833,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-05-31T13:39:02.000Z","date":"2023-05-26","kind":"purchase","planned":false,"acquired":true,"shares":126888,"price":0.0341,"value":4326.8808,"ownership":{"direct":true},"balance_after":91044217,"source":{"system":"sec-edgar","filing":"0001493152-23-019557","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223019557/ownership.xml","form_type":"4"}},{"id":1909118,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2023-05-02T21:00:46.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":0.045,"value":4500.0,"ownership":{"direct":true},"balance_after":90917329,"source":{"system":"sec-edgar","filing":"0001493152-23-015195","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315223015195/ownership.xml","form_type":"4"}},{"id":2093836,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-12-07T13:00:32.000Z","date":"2022-12-06","kind":"purchase","acquired":true,"shares":120000,"price":0.05,"value":6000.0,"ownership":{"direct":true},"balance_after":90558021,"source":{"system":"sec-edgar","filing":"0001493152-22-034663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222034663/ownership.xml","form_type":"4"}},{"id":2104607,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-11-25T14:00:38.000Z","date":"2022-11-22","kind":"purchase","acquired":true,"shares":70000,"price":0.08,"value":5600.0,"ownership":{"direct":true},"balance_after":90438021,"source":{"system":"sec-edgar","filing":"0001493152-22-033681","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222033681/ownership.xml","form_type":"4"}},{"id":2150132,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-09-28T13:15:09.000Z","date":"2022-09-26","kind":"purchase","acquired":true,"shares":20000,"price":0.068,"value":1360.0,"ownership":{"direct":true},"balance_after":90368021,"source":{"system":"sec-edgar","filing":"0001493152-22-026963","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222026963/ownership.xml","form_type":"4"}},{"id":2172227,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2022-08-29T13:15:14.000Z","date":"2022-08-25","kind":"purchase","acquired":true,"shares":80000,"price":0.082,"value":6560.0,"ownership":{"direct":true},"balance_after":90348021,"source":{"system":"sec-edgar","filing":"0001493152-22-024234","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315222024234/ownership.xml","form_type":"4"}},{"id":2576521,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-09-08T21:00:55.000Z","date":"2021-09-03","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022."}],"balance_after":225000,"derivative":{"exercise_price":0.1393,"expiration_date":"2031-09-03","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001493152-21-022220","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221022220/ownership.xml","form_type":"4"}},{"id":2632524,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Stock Options","published_at":"2021-07-16T21:38:27.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":513953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan and which vest immediately on the date of grant."}],"balance_after":513953,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":513953},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632523,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":5672,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5672025},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632522,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":13849,"ownership":{"direct":false,"nature":"By Autotelic, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13849161},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632521,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":false,"shares":74456,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares of the Series A Convertible Preferred Stock does not expire."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74455719},"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632520,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":5672025,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":6872529,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632519,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":13849161,"ownership":{"direct":false,"nature":"By Autotelic, Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":16780384,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632518,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":259302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant."}],"balance_after":90527323,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2632517,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHAIRMAN AND CEO"}}],"security":"Common Stock","published_at":"2021-07-16T21:38:27.000Z","date":"2021-03-31","kind":"exercise","acquired":true,"shares":74455719,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock (\"Series A Preferred\") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer."}],"balance_after":90268021,"source":{"system":"sec-edgar","filing":"0001493152-21-017106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017106/ownership.xml","form_type":"4"}},{"id":2970288,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2020-11-23T20:01:35.000Z","date":"2020-11-19","kind":"purchase","acquired":true,"shares":50500,"price":0.19,"value":9595.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.186 to $0.195 per share, inclusive. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15812308,"source":{"system":"sec-edgar","filing":"0001493152-20-022256","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022256/ownership.xml","form_type":"4"}},{"id":3193556,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2020-03-27T21:49:56.000Z","date":"2020-03-26","kind":"purchase","acquired":true,"shares":3000,"price":0.12,"value":360.0,"ownership":{"direct":true},"balance_after":15761808,"source":{"system":"sec-edgar","filing":"0001415889-20-000880","document":"form4-03272020_020342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000141588920000880/form4-03272020_020342.xml","form_type":"4"}},{"id":3797570,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-04T06:48:43.000Z","date":"2018-10-01","kind":"disposition_to_issuer","acquired":false,"shares":500000,"price":0.5,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Dr. Trieu also holds warrants to purchase 1,135,425 shares of common stock and 151.39 shares of Series E Convertible Preferred Stock (which shares are initially convertible into 1,513,900 shares of common stock)."}],"balance_after":612716,"source":{"system":"sec-edgar","filing":"0001493152-18-014069","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218014069/ownership.xml","form_type":"4"}},{"id":3961629,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants to Purchase Common Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"purchase","acquired":true,"shares":2564465,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Autotelic Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"In connection with the closing of the Offering, the issuer and Autotelic Inc., of which entity the reporting person serves as Chairman of the Board, agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to Autotelic Inc. under that certain Master Services Agreement dated November 15, 2016 between the issuer and Autotelic Inc. by the issuance by the issuer to Autotelic Inc. of 162.59 shares of Series E Convertible Preferred Stock and warrants to purchase 1,219,425 shares of common stock. The issuer also issued to Autotelic Inc, an additional 1,345,040 warrants pursuant to the Master Services Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrants expire on the five year anniversary of the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities are held by Autotelic Inc., of which entity the reporting person serves as Chairman of the Board."}],"balance_after":2564465,"derivative":{"exercise_price":0.55,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":2564465},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961628,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series E Convertible Preferred Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"purchase","acquired":true,"shares":162.59,"price":5000,"value":812950.0,"ownership":{"direct":false,"nature":"By Autotelic Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"In connection with the closing of the Offering, the issuer and Autotelic Inc., of which entity the reporting person serves as Chairman of the Board, agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to Autotelic Inc. under that certain Master Services Agreement dated November 15, 2016 between the issuer and Autotelic Inc. by the issuance by the issuer to Autotelic Inc. of 162.59 shares of Series E Convertible Preferred Stock and warrants to purchase 1,219,425 shares of common stock. The issuer also issued to Autotelic Inc, an additional 1,345,040 warrants pursuant to the Master Services Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities are held by Autotelic Inc., of which entity the reporting person serves as Chairman of the Board."}],"balance_after":162.59,"derivative":{"exercise_price":0.5,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":1625900},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961627,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"5% Demand Line of Credit","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":false,"price":0,"reported_value":90816,"ownership":{"direct":false,"nature":"By Autotelic Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"On April 16, 2018, Autotelic Inc., an entity of which the reporting person serves as Chairman of the Board, and the issuer amended the demand line of credit that was extended by Autotelic Inc. to the issuer on April 4, 2017 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 19 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 142,500 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the line of credit has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"N/A"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F11","text":"The line of credit converted into 19 shares of Series E Convertible Preferred Stock and warrants to purchase 142,500 shares of common stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F11","text":"The line of credit converted into 19 shares of Series E Convertible Preferred Stock and warrants to purchase 142,500 shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities are held by Autotelic Inc., of which entity the reporting person serves as Chairman of the Board."}],"derivative":{"exercise_price":5000,"exercise_date":"2018-04-16","underlying":"Preferred Stock / Warrants"},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961626,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants to Purchase Common Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":true,"shares":142500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Autotelic Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"On April 16, 2018, Autotelic Inc., an entity of which the reporting person serves as Chairman of the Board, and the issuer amended the demand line of credit that was extended by Autotelic Inc. to the issuer on April 4, 2017 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 19 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 142,500 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the line of credit has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrants expire on the five year anniversary of the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities are held by Autotelic Inc., of which entity the reporting person serves as Chairman of the Board."}],"balance_after":142500,"derivative":{"exercise_price":0.55,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":142500},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961625,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series E Convertible Preferred Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":true,"shares":19,"price":5000,"value":95000.0,"ownership":{"direct":false,"nature":"By Autotelic Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F9","text":"On April 16, 2018, Autotelic Inc., an entity of which the reporting person serves as Chairman of the Board, and the issuer amended the demand line of credit that was extended by Autotelic Inc. to the issuer on April 4, 2017 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 19 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 142,500 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the line of credit has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The securities are held by Autotelic Inc., of which entity the reporting person serves as Chairman of the Board."}],"balance_after":19,"derivative":{"exercise_price":0.5,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961624,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"5% Demand Line of Credit","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":false,"price":0,"reported_value":540000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On April 16, 2018, the reporting person and the issuer amended the demand line of credit that was extended by the reporting person to the issuer on November 15, 2016 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 114.63 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 859,725 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the line of credit has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"N/A"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F8","text":"The line of credit converted into 114.63 shares of Series E Convertible Preferred Stock and warrants to purchase 859,725 shares of common stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"The line of credit converted into 114.63 shares of Series E Convertible Preferred Stock and warrants to purchase 859,725 shares of common stock."}],"derivative":{"exercise_price":5000,"exercise_date":"2016-11-15","underlying":"Preferred Stock / Warrants"},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961623,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants to Purchase Common Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":true,"shares":859725,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On April 16, 2018, the reporting person and the issuer amended the demand line of credit that was extended by the reporting person to the issuer on November 15, 2016 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 114.63 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 859,725 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the line of credit has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrants expire on the five year anniversary of the closing of the Offering."}],"balance_after":859725,"derivative":{"exercise_price":0.55,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":859725},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961622,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series E Convertible Preferred Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":true,"shares":114.63,"price":5000,"value":573150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On April 16, 2018, the reporting person and the issuer amended the demand line of credit that was extended by the reporting person to the issuer on November 15, 2016 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 114.63 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 859,725 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the line of credit has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock."}],"balance_after":114.63,"derivative":{"exercise_price":0.5,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":1146300},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961621,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"5% Convertible Promissory Note","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":false,"price":0,"reported_value":165634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On April 16, 2018, the reporting person and the issuer amended the convertible promissory note in the principal amount of $165,634 that the issuer issued to the reporting person in June 2017 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 34.51 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 258,825 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the note has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"N/A"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F6","text":"The note converted into 34.51 shares of Series E Convertible Preferred Stock and warrants to purchase 258,825 shares of common stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"The note converted into 34.51 shares of Series E Convertible Preferred Stock and warrants to purchase 258,825 shares of common stock."}],"derivative":{"exercise_price":5000,"exercise_date":"2018-04-16","underlying":"Preferred Stock / Warrants"},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961620,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants to Purchase Common Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":true,"shares":258825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On April 16, 2018, the reporting person and the issuer amended the convertible promissory note in the principal amount of $165,634 that the issuer issued to the reporting person in June 2017 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 34.51 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 258,825 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the note has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrants expire on the five year anniversary of the closing of the Offering."}],"balance_after":258825,"derivative":{"exercise_price":0.55,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":258825},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961619,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series E Convertible Preferred Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"exercise","acquired":true,"shares":34.51,"price":5000,"value":172550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On April 16, 2018, the reporting person and the issuer amended the convertible promissory note in the principal amount of $165,634 that the issuer issued to the reporting person in June 2017 so that the unpaid principal amount thereof, together with accrued but unpaid interest thereon, would be converted into 34.51 shares of the issuer's Series E Convertible Preferred Stock and warrants to purchase up to 258,825 shares of the issuer's common stock upon the closing of the Offering. As a result of such conversion, the note has been satisfied in full and is no longer outstanding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock."}],"balance_after":34.51,"derivative":{"exercise_price":0.5,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":345100},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961618,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants to Purchase Common Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"grant","acquired":true,"shares":16875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the \"Offering\"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 2.25 shares of Series E Preferred Stock and warrants to purchase 16,875 shares of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The warrants expire on the five year anniversary of the closing of the Offering."}],"balance_after":16875,"derivative":{"exercise_price":0.55,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":16875},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":3961617,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series E Convertible Preferred Stock","published_at":"2018-04-18T21:40:40.000Z","date":"2018-04-16","kind":"grant","acquired":true,"shares":2.25,"price":5000,"value":11250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the \"Offering\"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 2.25 shares of Series E Preferred Stock and warrants to purchase 16,875 shares of common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock."}],"balance_after":2.25,"derivative":{"exercise_price":0.5,"exercise_date":"2018-04-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001493152-18-005444","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315218005444/form4.xml","form_type":"4"}},{"id":4115587,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"Options to purchase common stock","published_at":"2018-01-03T18:34:53.000Z","date":"2018-01-03","kind":"grant","acquired":true,"shares":3800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase 1,900 shares of common stock are exercisable beginning on January 3, 2018, and options to purchase 1,900 shares of common stock are exercisable beginning on January 3, 2019."}],"balance_after":3800,"derivative":{"exercise_price":1.56,"expiration_date":"2023-01-03","underlying":"common stock","underlying_shares":3800},"source":{"system":"sec-edgar","filing":"0001587074-18-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000158707418000001/primary_doc.xml","form_type":"4"}},{"id":4266725,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Executive Chairman"}}],"security":"5% Convertible Promissory Note","published_at":"2017-07-05T16:31:15.000Z","date":"2017-06-30","kind":"grant","acquired":true,"price":165634,"reported_value":165634,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The holders of a majority of the aggregate principal amount of the convertible promissory notes that were issued by the registrant in the offering of which the note purchased by the reporting person is a part have the right to elect to convert the entire unpaid principal amount (and accrued interest) of such notes into the common stock of the registrant on the maturity date of such notes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"N/A"}],"balance_after":473240,"derivative":{"exercise_price":0.35,"exercise_date":"2018-06-01","underlying":"Common Stock","underlying_shares":473240},"source":{"system":"sec-edgar","filing":"0001493152-17-007488","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315217007488/form4.xml","form_type":"4"}},{"id":4286478,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-06-12T17:00:15.000Z","date":"2017-06-09","kind":"purchase","acquired":true,"shares":10000,"price":0.39,"value":3900.0,"ownership":{"direct":true},"balance_after":11127141,"source":{"system":"sec-edgar","filing":"0001493152-17-006494","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315217006494/form4.xml","form_type":"4"}},{"id":4289197,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-06-08T18:30:13.000Z","date":"2017-06-07","kind":"purchase","acquired":true,"shares":2500,"price":0.38,"value":950.0,"ownership":{"direct":true},"balance_after":11097141,"source":{"system":"sec-edgar","filing":"0001493152-17-006346","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315217006346/form4.xml","form_type":"4"}},{"id":4289196,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-06-08T18:30:13.000Z","date":"2017-06-08","kind":"purchase","acquired":true,"shares":20000,"price":0.39,"value":7800.0,"ownership":{"direct":true},"balance_after":11117141,"source":{"system":"sec-edgar","filing":"0001493152-17-006346","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315217006346/form4.xml","form_type":"4"}},{"id":4462848,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-02-08T17:30:20.000Z","date":"2017-02-06","kind":"purchase","acquired":true,"shares":862068,"price":0.29,"value":249999.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held by Lipomedics Inc., of which entity the reporting person serves as Chairman of the Board and Chief Operating Officer."}],"balance_after":862068,"source":{"system":"sec-edgar","filing":"0001493152-17-001242","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315217001242/form4.xml","form_type":"4"}},{"id":4506167,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Options to purchase common stock","published_at":"2017-01-04T18:27:03.000Z","date":"2017-01-03","kind":"grant","acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017, and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018."}],"balance_after":81000,"derivative":{"exercise_price":0.17,"expiration_date":"2022-01-03","underlying":"common stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001493152-17-000148","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315217000148/form4.xml","form_type":"4"}},{"id":4546336,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2016-11-22T16:02:08.000Z","date":"2016-11-15","kind":"grant","acquired":true,"shares":5255354,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for 500,000 shares of the common stock of Ithena pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares held by Autotelic Inc., of which entity the reporting person serves as Chairman of the Board."}],"balance_after":5255354,"source":{"system":"sec-edgar","filing":"0001493152-16-015386","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315216015386/form4.xml","form_type":"4"}},{"id":4546335,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2016-11-22T16:02:08.000Z","date":"2016-11-15","kind":"grant","acquired":true,"shares":23123558,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 2,200,000 shares of the common stock of Ithena pursuant to the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares held by Autotelic LLC, of which entity the reporting person serves as Chief Executive Officer."}],"balance_after":23123558,"source":{"system":"sec-edgar","filing":"0001493152-16-015386","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315216015386/form4.xml","form_type":"4"}},{"id":4546334,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30640,"kind":"person","name":"Trieu Vuong","position":1,"cik":"0001587074","reported_name":"Trieu Vuong","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Common Stock","published_at":"2016-11-22T16:02:08.000Z","date":"2016-11-15","kind":"grant","acquired":true,"shares":11094641,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 1,055,556 shares of the common stock of IthenaPharma Inc. (\"Ithena\") pursuant to that certain Agreement and Plan of Merger dated as of November 15, 2016 by and among Marina Biotech, Inc. (the \"Issuer\"), Ithena Acquisition Corporation (a wholly-owned subsidiary of the Issuer), Ithena, and Vuong Trieu as the representative of Ithena (the \"Merger Agreement\")."}],"balance_after":11094641,"source":{"system":"sec-edgar","filing":"0001493152-16-015386","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000149315216015386/form4.xml","form_type":"4"}}]}